J. Armstrong

6.4k total citations
51 papers, 2.0k citations indexed

About

J. Armstrong is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, J. Armstrong has authored 51 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Epidemiology. Recurrent topics in J. Armstrong's work include Prostate Cancer Treatment and Research (17 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Antibiotic Resistance in Bacteria (7 papers). J. Armstrong is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Antibiotic Resistance in Bacteria (7 papers). J. Armstrong collaborates with scholars based in United Kingdom, United States and Germany. J. Armstrong's co-authors include Paul Newell, Leanne B. Gasink, Greg Stone, Peter Iversen, Thomas Morris, Manfred P. Wirth, Angela Wardman, Yehuda Carmeli, William A. See and David G. McLeod and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and Annals of Surgery.

In The Last Decade

J. Armstrong

51 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Armstrong United Kingdom	23	907	745	560	554	392	51	2.0k
Luis M. Beltrán Spain	16	337 0.4×	135 0.2×	254 0.5×	139 0.3×	131 0.3×	50	1.1k
Laura Lladó Spain	27	149 0.2×	113 0.2×	836 1.5×	391 0.7×	32 0.1×	151	2.6k
Yulin Feng China	21	131 0.1×	67 0.1×	208 0.4×	564 1.0×	67 0.2×	51	1.3k
Nobuo Murakami Japan	23	49 0.1×	119 0.2×	360 0.6×	119 0.2×	138 0.4×	93	2.3k
Brian Warren South Africa	18	56 0.1×	83 0.1×	992 1.8×	341 0.6×	37 0.1×	28	2.4k
Nikolaos Andreatos United States	24	96 0.1×	39 0.1×	444 0.8×	308 0.6×	121 0.3×	60	2.0k
José Blanquer Spain	25	64 0.1×	91 0.1×	1.1k 2.0×	339 0.6×	62 0.2×	63	1.7k
Samir Patel United States	29	53 0.1×	47 0.1×	543 1.0×	474 0.9×	36 0.1×	135	2.9k
Jennifer Kranz Germany	17	89 0.1×	49 0.1×	520 0.9×	165 0.3×	50 0.1×	136	1.2k
A. Descorps-Declère France	13	74 0.1×	40 0.1×	481 0.9×	141 0.3×	102 0.3×	24	1.2k

Countries citing papers authored by J. Armstrong

Since Specialization

Citations

This map shows the geographic impact of J. Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Armstrong more than expected).

Fields of papers citing papers by J. Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Armstrong. The network helps show where J. Armstrong may publish in the future.

Co-authorship network of co-authors of J. Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of J. Armstrong. A scholar is included among the top collaborators of J. Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Armstrong. J. Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reinmuth, Niels, Óscar Juan, Dariusz M. Kowalski, et al.. (2024). Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study. Clinical Cancer Research. 30(18). 4055–4067. 5 indexed citations

Wildsmith, Sophie, Jiabu Ye, Giovanni Melillo, et al.. (2022). Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. Cancer Research Communications. 2(1). 39–48. 7 indexed citations

Abou‐Alfa, Ghassan K., Stephen L. Chan, Junji Furuse, et al.. (2018). A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.. Journal of Clinical Oncology. 36(15_suppl). TPS4144–TPS4144. 78 indexed citations

Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, et al.. (2017). Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study. Annals of Oncology. 28. v372–v372. 24 indexed citations

Wagenlehner, Flo ri an, Jack D. Sobel, Paul Newell, et al.. (2016). Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clinical Infectious Diseases. 63(6). 754–762. 259 indexed citations

Carmeli, Yehuda, J. Armstrong, Peter J. Laud, et al.. (2016). Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. The Lancet Infectious Diseases. 16(6). 661–673. 319 indexed citations

Mazuski, John E., Leanne B. Gasink, J. Armstrong, et al.. (2016). Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clinical Infectious Diseases. 62(11). 1380–1389. 287 indexed citations

Nicolau, David P., Leonard Siew, J. Armstrong, et al.. (2015). Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy. 70(10). 2862–2869. 106 indexed citations

Morgan, David, Kwok M. Ho, J. Armstrong, & Edward Litton. (2014). Long-term Clinical Outcomes and Health Care Utilization After Bariatric Surgery. Annals of Surgery. 262(1). 86–92. 44 indexed citations

10.

Wong, Annette, Dick C. Chan, J. Armstrong, & Gerald F. Watts. (2010). Effect of laparoscopic sleeve gastrectomy on elevated C-reactive protein and atherogenic dyslipidemia in morbidly obese patients. Clinical Biochemistry. 44(4). 342–344. 25 indexed citations

11.

Iversen, Peter, David G. McLeod, William A. See, et al.. (2010). Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. British Journal of Urology. 105(8). 1074–1081. 78 indexed citations

12.

Reiter, Edward O., Nelly Mauras, Bindu Kulshreshtha, et al.. (2010). Bicalutamide plus Anastrozole for the Treatment of Gonadotropin-Independent Precocious Puberty in Boys with Testotoxicosis: A Phase II, Open-Label Pilot Study (BATT). Journal of Pediatric Endocrinology and Metabolism. 23(10). 999–1009. 36 indexed citations

13.

Phillips, Kelly‐Anne, et al.. (2009). Breast cancer testing strategies and the utilization of targeted therapies: Data from the real world. Journal of Clinical Oncology. 27(15_suppl). e17518–e17518. 1 indexed citations

14.

Armstrong, J., et al.. (2009). Outcomes of sleeve gastrectomy for morbid obesity: A safe and effective procedure?. International Journal of Surgery. 8(1). 69–71. 39 indexed citations

15.

Muneyyirci‐Delale, Ozgul, Gloria Richard-Davis, Tom Morris, & J. Armstrong. (2007). Goserelin Acetate 10.8 mg Plus Iron Versus Iron Monotherapy Prior to Surgery in Premenopausal Women with Iron-Deficiency Anemia Due to Uterine Leiomyomas: Results from a Phase III, Randomized, Multicenter, Double-Blind, Controlled Trial. Clinical Therapeutics. 29(8). 1682–1691. 13 indexed citations

16.

Wirth, Manfred P., C. Tyrrell, K.P.J. Delaere, et al.. (2006). Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer and Prostatic Diseases. 10(1). 87–93. 22 indexed citations

17.

Robertson, J.F.R., Semiglazov Vf, Gia Nemsadze, et al.. (2006). Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. European Journal of Cancer. 43(1). 64–70. 26 indexed citations

18.

Tyrrell, C., William A. See, David G. McLeod, et al.. (2005). Bicalutamide (‘Casodex’) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology. 76(1). 4–10. 50 indexed citations

19.

McLeod, David G., Peter Iversen, William A. See, et al.. (2005). Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. British Journal of Urology. 97(2). 247–254. 196 indexed citations

20.

Wirth, M., CJ Tyrrell, K.P.J. Delaere, et al.. (2005). Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases. 8(2). 194–200. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact